

The *P. gingivalis* Autocitrullinome Is Not a Target for ACPA in Early Rheumatoid Arthritis

Journal of Dental Research
2020, Vol. 99(4) 456–462
© The Author(s) 2020



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0022034519898144
journals.sagepub.com/home/jdr

E. Muñoz-Atienza^{1*}, M.B. Flak^{1*}, J. Sirr¹, N.A. Paramonov², J. Aduse-Opoku², C. Pitzalis¹, and M.A. Curtis²

Abstract

Rheumatoid arthritis (RA), a chronic inflammatory disease affecting primarily the joints, is frequently characterized by the presence of autoimmune anticitrullinated protein antibodies (ACPA) during preclinical stages of disease and accumulation of hypercitrullinated proteins in arthritic joints. A strong association has been reported between RA and periodontal disease, and *Porphyromonas gingivalis*, a known driver of periodontitis, has been proposed as the microbial link underlying this association. We recently demonstrated *P. gingivalis*-mediated gut barrier breakdown and exacerbation of joint inflammation during inflammatory arthritis. In the present study, we investigated another potential role for *P. gingivalis* in RA etiopathogenesis, based on the generation of ACPA through the activity of a unique *P. gingivalis* peptidylarginine deiminase (PPAD) produced by this bacterium, which is capable of protein citrullination. Using a novel *P. gingivalis* VV50 PPAD mutant strain, incapable of protein citrullination, and serum from disease-modifying antirheumatic drug-naïve early arthritis patients, we assessed whether autocitrullinated proteins in the *P. gingivalis* proteome serve as cross-activation targets in the initiation of ACPA production. We found no evidence for patient antibody activity specific to autocitrullinated *P. gingivalis* proteins. Moreover, deletion of PPAD did not prevent *P. gingivalis*-mediated intestinal barrier breakdown and exacerbation of disease during inflammatory arthritis in a murine model. Together, these findings suggest that the enzymatic activity of PPAD is not a major virulence mechanism during early stages of inflammatory arthritis.

Keywords: *P. gingivalis* peptidylarginine deiminase, autoimmune responses, chronic inflammation, periodontitis, microbiota, immunocrossreactivity

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the joints and is driven by an autoimmune response. Left untreated, RA leads to progressive deterioration of the synovial lining, resulting in joint erosion, debilitating pain, and, ultimately, permanent disability. The presence of autoantibodies in the serum is characteristic for the majority of patients with RA. The most prominent among these are rheumatoid factor and IgG anticitrullinated protein antibodies (ACPA), which are used as diagnostic biomarkers and for stratification (Rantapaa-Dahlqvist et al. 2003), and are associated with poor outcomes (Kapetanovic et al. 2006). Accumulation of hypercitrullinated proteins in RA joints has been observed (Romero et al. 2013). ACPA, which target a range of citrullinated autoantigens (Sakkas et al. 2017), can be detected during the very early stages of RA (Kudo-Tanaka et al. 2007), suggesting a role in the initiation phase of the disease. The cause of RA, however, remains undefined (Maeda and Takeda 2017).

Increasing evidence is emerging for a strong association between RA and periodontal disease (Maeda and Takeda 2017). *Porphyromonas gingivalis*, based on its detection at periodontitis-affected sites in humans (Condorelli et al. 1998) and observed pathogenicity in animal models of periodontitis (Hajishengallis et al. 2011), is sometimes referred to as a keystone pathogen in the etiopathogenesis of periodontitis. To date, however, this keystone role has been established only in

preclinical models of disease where it is able to induce oral dysbiosis, manipulate host immune responses, and drive local inflammation (Hajishengallis et al. 2011).

Another proposed etiopathogenic mechanism in RA, corroborated by the associations between RA and periodontal disease, is the mounting of a host immune response against pathogenic microbes, including *P. gingivalis*. Interestingly, *P. gingivalis* possesses a unique prokaryotic citrullinating enzyme, *P. gingivalis* peptidylarginine deiminase (PPAD; McGraw et al. 1999). Unlike human peptidylarginine deiminases, which preferentially citrullinate internal arginine residues on target proteins, citrullination by PPAD occurs exclusively on carboxy-terminal arginine residues, which are generated through protein cleavage by the microbe's arginine

¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, London, UK

²Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK

*Authors contributing equally to this article.

A supplemental appendix to this article is available online.

Corresponding Author:

M.B. Flak, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, QMUL, Charterhouse Square, London EC1M 6BQ, UK.
Email: m.b.flak@qmul.ac.uk

gingipains (Goulas et al. 2015; Montgomery et al. 2016). PPAD activity has not yet been formally demonstrated at sites of periodontitis. However, as *P. gingivalis* has been isolated from such sites (Condorelli et al. 1998) and because PPAD is expressed mainly on the surface of this bacterium (McGraw et al. 1999; Quirke et al. 2014), PPAD activity at sites of periodontal inflammation can be inferred. Thus, assuming PPAD activity in gingiva, the discrepancy in citrullination target sites between human peptidylarginine deiminase and PPAD may enhance the antigenicity of microbial autocitrullinated proteins (Sakkas et al. 2017). In the susceptible host, as originally hypothesized by Rosenstein and colleagues (2004), this initially antimicrobial response could give rise to cross-reactive antibodies able to target citrullinated host proteins (Masson-Bessiere et al. 2001).

The putative role of autocitrullinated *P. gingivalis* proteins in the etiopathogenesis of RA remains of interest. Herein we report that deleting PPAD from the *P. gingivalis* W50 genome ablated its ability to citrullinate protein-bound arginine residues. Using sera from disease-modifying antirheumatic drug (DMARD)-naïve early RA patients, we found that the autocitrullinated proteome of *P. gingivalis* W50 was not specifically targeted by ACPA in RA patients. Deletion of PPAD did not reverse the ability of *P. gingivalis* to promote intestinal barrier disruption and exacerbation of joint disease in a model of inflammatory arthritis.

Our findings indicate that although PPAD is capable of citrullinating the endogenous *P. gingivalis* proteome, these citrullinated proteins do not represent major targets for autoimmune responses in early RA patients and suggest that the role for PPAD activity in driving pathology in inflammatory arthritis is limited.

Materials and Methods

The Appendix Materials and Methods describe the methods, materials, reagents, and sources for the following: RA patient and healthy control sera; bacterial strains used and growth conditions; generation of *P. gingivalis* mutant strain PG1424; PPAD activity measurement by colorimetric assay and thin layer chromatography (TLC); SDS-PAGE and immunoblotting, including antimodified citrulline method; preabsorbed serum ACPA titration ELISA; induction of inflammatory arthritis by K/BxN serum transfer and inoculation with bacteria; 16S rRNA gene quantitative polymerase chain reaction (16S qPCR); and statistical analysis. Animal experiments conform to the ARRIVE guidelines (see the Appendix and ARRIVE checklist).

Results

Deletion of PPAD from *P. gingivalis* W50 Ablates Its Ability to Citrullinate Protein-Bound Arginine

As conflicting results have been reported pertaining to the role of autocitrullinated *P. gingivalis* proteins in RA, we addressed this question by generating a PPAD-mutant *P. gingivalis* strain lacking citrullination activity (PG1424) by homologous

replacement of the *ppad*-encoding region PG1424 with an *ermF-ermAM* cassette encoding a clindamycin resistance gene (see Appendix Methods and Appendix Fig. 1 for details).

To assess the effect of PPAD deletion from *P. gingivalis* W50, we first compared the citrullination activity of *P. gingivalis* wild type (W50), a gingipain protease (*rgpA*, *rgpB*)-deficient mutant (E8; Aduse-Opoku 2006), and the PPAD-deficient mutant (PG1424). Bacterial cells (1×10^8 CFU [colony-forming units]) were incubated with 5mM N- α -benzoyl-L-arginine methyl ester (BAME), N- α -benzoyl-L-arginine (BA), or free L-arginine under anaerobic conditions at 37 °C overnight, followed by removal of the bacterial cells. Using a colorimetric assay to measure L-citrulline levels in the supernatants, we observed complete ablation of BAME and BA citrullination when the substrate was incubated with PG1424 as compared with incubations with W50 (Fig. 1A). We also measured a 18% reduction in BAME citrullination by E8 but no significant reduction in BA citrullination, suggesting a limited role for arg-gingipain-mediated cleavage of L-arginine methyl ester substrates in facilitating citrullination.

Next, *P. gingivalis* strains W50, E8, or PG1424 were incubated with both substrates as before; bacterial cells were removed by centrifugation; and supernatants were run on a TLC plate. Incubation of both substrates with *P. gingivalis* W50 or E8 yielded spots corresponding to N- α -benzoyl-L-citrulline (BC), and no BA or BAME was detected in these lanes (Fig. 1B), indicating complete conversion of the substrates. Conversely, lanes containing incubations of BA or BAME with PG1424 showed strong spots corresponding to the input substrate, but no citrullinated products were detected. Of note, incubation of E8 with BAME also produced detectable levels of N- α -benzoyl-L-citrulline methyl ester (BCME), suggesting that the absence of arginine gingipain activity may result in the further conversion of BAME to BCME.

Citrullination of free L-arginine, as assessed by colorimetric assay and TLC, was not affected by deletion of PPAD (Fig. 1A, C). Arginine deiminases (ADIs), guanidino group-modifying enzymes able to citrullinate free arginine, have been described in other bacterial taxa (Casiano-Colon and Marquis 1988; Díez et al. 2017; Cai et al. 2018). Genomic sequence comparisons with ADI proteins found in other bacterial species with the RAST database (<http://rast.nmpdr.org/rast.cgi>) identified orthologous areas in the *P. gingivalis* genome (see black box in Fig. 1D), suggesting the presence of an ADI gene in the *P. gingivalis* W50 genome, which could be responsible for the observed free L-arginine citrullination.

Next, using the *P. gingivalis* wild-type W50 and mutant PG1424, we investigated the role of PPAD in the autocitrullination of the *P. gingivalis* W50 proteome. Autocitrullinated *P. gingivalis* proteins have been proposed as triggers of autoimmune responses in RA (Wegner et al. 2010; Quirke et al. 2014). To compare citrullination of proteins in *P. gingivalis* W50 and PG1424, whole cell lysates were prepared in the presence of protease inhibitor leupeptin (2 mM, +Leu; Curtis et al. 2002), or leupeptin was added after 10 min of lysis (-Leu; see Appendix Methods). Citrullinated proteins were measured by immunoblot with an antimodified citrulline antibody (Shi




Figure 1. *Porphyromonas gingivalis* peptidylarginine deiminase (PPAD) activity can be detected in the wild-type but not the PPAD-mutant *P. gingivalis* strain. (A) Percentage of PPAD activity in *P. gingivalis* E8 (*rgpA-rgpB* mutant) and PG1424 (*ppad* mutant) in comparison with *P. gingivalis* W50 (wild-type strain) measured by colorimetric assay. Results are expressed as mean \pm SEM. * $P < 0.05$. **** $P < 0.0001$. One-way analysis of variance, followed by Tukey's multiple-comparisons test on the raw data. BA, N- α -benzoyl-L-arginine; BAME, N- α -benzoyl-L-arginine methyl ester; BC, N- α -benzoyl-L-citrulline; BCME, N- α -benzoyl-L-citrulline methyl ester. (B) BC and BCME produced by *P. gingivalis* strains W50, E8, and PG1424 after incubation with BA or BAME were measured by thin layer chromatography. (C) L-citrulline production from L-arginine by *P. gingivalis* strains W50, E8, and PG1424 was assessed by thin layer chromatography. (D) Sequence comparisons of the *P. gingivalis* genome with arginine deiminases (in box) of other bacterial species to identify orthologous protein sequences. (E) Comparison of autocitrullination in *P. gingivalis* W50 and PG1424. Immunoblotting of whole cell lysates from *P. gingivalis* W50 and PG1424 prepared with immediate addition of leupeptin (+Lp) or delayed addition (-Lp; after 10 min of lysis) was carried out via the antimodified citrulline method, including native histone H2A (nH2A; negative control) and citrullinated histone H2A (ch2A; positive control).

et al. 2013). Citrullination was detected in lanes from *P. gingivalis* W50 colonies prepared in the presence of leupeptin, indicating the presence of citrullinated proteins in the original bacterial sample (Fig. 1E). However, we detected higher levels of citrullinated proteins if leupeptin was added to the lysis reactions after a 10-min delay, indicative of autocitrullination of C-terminal arginine residues generated by the action of arginoglypains during the lysis period. No citrullinated proteins were detected in lanes containing any of the PG1424 lysates.

Taken together, these findings indicate that PPAD enzymatic activity is nonredundant for autocitrullination of the *P. gingivalis* W50 proteome as well as other substrates that

have a C-terminal arginine. Moreover, *P. gingivalis* W50 PPAD retains its enzymatic activity after lysis of bacterial cells.

Autocitrullinated Proteins in the *P. gingivalis* W50 Proteome Are Not Targeted by ACPA in Serum from Early RA Patients

To assess potential systemic antibody responses in ACPA+ RA patients to autocitrullinated *P. gingivalis* proteins, we devised a preabsorbed serum ACPA titration ELISA to compare serum ACPA binding activity against the autocitrullinated and

noncitrullinated *P. gingivalis* cellular proteome. Serum from DMARD-naïve ACPA+ and ACPA- early RA patients and from healthy controls was incubated in microtiter plate wells coated with total cell lysates collected from *P. gingivalis* W50 or PG1424 or bovine serum albumin (BSA)-coated control wells. Next, unbound ACPA in the preabsorbed sera were measured by anti-CCP ELISA. As expected, high levels of ACPA were detected for sera from ACPA+ RA patients that had been preabsorbed in BSA-coated control wells, while low amounts of ACPA were measured in BSA-preabsorbed sera from ACPA- RA patients and healthy controls (Fig. 2A). Of note, no differences in ACPA levels were detected between ACPA+ sera preabsorbed against lysates from W50 and PG1424 *P. gingivalis* strains, and levels were comparable to the BSA control, suggesting that no significant amounts of ACPA had bound to either W50 or PG1424 lysates.

We next assessed whether differences in human serum IgG antibody reactivity were discernable when immunoreactivity was compared against proteins within the entire microbial proteome. *P. gingivalis* W50 and PG1424 was grown for 48 h in liquid culture, and whole cell lysates and supernatants were collected, followed by immunoblotting with the sera of ACPA+ and ACPA- RA patients and healthy controls. Visual comparison of individual bands in entire lanes detected some differences in the banding patterns among different serum donors for whole cell lysates and supernatants (Fig. 2B, D; 2 representative donors per group are shown); however, we did not observe differences in band patterns between *P. gingivalis* W50 and PG1424 whole cell lysates or supernatants when serum from the same donor was used (Fig. 2B, D). Of note, no associations were detected between banding patterns of *P. gingivalis* W50 and PG1424 with sera from ACPA+ or ACPA- RA patients or healthy control groups. Densitometric quantification of total band intensities in each lane indicated that there were no differences in the immunoreactivity of patient or healthy control sera against total autocitrullinated versus noncitrullinated proteomes in whole cell lysates or supernatants (Fig. 2C, E), in line with the results from the serum preabsorption assay (Fig. 2A). Given our observation that *P. gingivalis* proteins preferentially citrullinated by PPAD are approximately 11 kDa (Fig. 1E), we queried whether citrullinated




Figure 2. Human serum immunoreactivity against lysates from citrullination-competent and citrullination-incompetent *Porphyromonas gingivalis* does not differ. (A) Preabsorbed serum anticitrullinated protein antibodies (ACPA) titration was performed by preabsorbing sera from ACPA+, ACPA- rheumatoid arthritis (RA) patients, and healthy control (HC) sera on microtiter plates coated with whole cell lysates from *P. gingivalis* W50, PG1424, or 10% bovine serum albumin (BSA; negative control), followed by detection of remaining serum ACPA with anti-CCP ELISA. Results are expressed as mean \pm SEM. $**P \leq 0.01$. $***P \leq 0.001$. One-way analysis of variance, followed by Sidak's post hoc test. (B-E) Assessment of human serum immunoreactivity against specific components in lysates from citrullinated-competent and citrullinated-deficient *P. gingivalis*. Representative immunoblots are shown of (B) whole cell lysates and (D) supernatants from *P. gingivalis* W50 (W) and PG1424 (P) probed with serum from ACPA+ and ACPA- RA patients and healthy controls and horseradish peroxidase-conjugated anti-human IgG antibody. Arrow in panel B indicates band used for analysis in panel F. (C, E) Corresponding densitometry analysis of band intensity on immunoblots. Results in scatter-dot plots are expressed as mean \pm SEM and unpaired student's *t* test comparing W50 and PG1424 in each serum group. (F) Densitometry analysis of 11-kDa band (arrow in B) intensity on immunoblots of W50 or PG1424 whole cell lysates incubated with ACPA+ RA patient serum. Results are presented as mean \pm SEM and unpaired Student's *t* test.

proteins within this band, specifically, could be targets for ACPA from early ACPA+ RA patients. Densitometric analysis indicated that binding of patient serum antibodies to proteins within the 11-kDa band did not significantly differ between citrullinated *P. gingivalis* W50 and noncitrullinated PG1424 lysates (Fig. 2F).

Together, these data suggest that ACPA+ or ACPA- RA patients' serum IgG antibodies do not specifically target autocitrullinated over noncitrullinated *P. gingivalis* proteins.




Figure 3. Gut barrier breakdown and exacerbation of joint inflammation during inflammatory arthritis are not prevented by peptidylarginine deiminase deletion. Mice were orally inoculated with *Porphyromonas gingivalis* W50 or PG1424 (10^9 colony-forming units per mouse) or given vehicle (phosphate-buffered saline [PBS]) on days -1 , 1 , and 3 and injected with K/BxN serum ($50 \mu\text{L}/\text{mouse}$, intraperitoneal, days 0 and 2). Mesenteric lymph nodes were collected on day 8 . **(A)** 16S rRNA gene levels were measured in mesenteric lymph nodes by 16S quantitative polymerase chain reaction to assess bacterial translocation across the intestinal barrier. Results are presented as mean \pm SEM and representative of 3 or 4 mice per group. $*P \leq 0.05$. Mann-Whitney test. **(B)** Swelling indices of edema formation on day 7 in paws and ankles of 4 mice per group. $*P \leq 0.05$. Results are presented as median, interquartile range, and 95% CI. One-way analysis of variance, followed by Sidak's post hoc test. **(C)** Daily clinical arthritis scores were recorded over time. Results are presented as mean \pm SEM for 4 mice per time point per group. **(D)** Clinical arthritis score on day 8 . Results are presented as mean \pm SEM for 4 mice per group. $*P \leq 0.05$. One-way analysis of variance, followed by Sidak's post hoc test.

PPAD Deletion Does Not Prevent *P. gingivalis*-Induced Gut Barrier Breakdown and Exacerbation of Joint Inflammation during Inflammatory Arthritis

We recently reported on the pathogenic actions of *P. gingivalis* in exacerbating arthritic inflammation by breaking down the intestinal barrier and promoting the breach of gut microbes into host tissues (Flak et al. 2019). These effects were not observed if animals were inoculated with a commensal microbe, suggesting that this mechanism is specific to pathobionts such as *P. gingivalis*.

Hence, we next sought to evaluate whether PPAD contributes to the observed pathogenic actions, using our model of induced inflammatory arthritis. For this purpose, C57BL/6 mice were orally inoculated with 10^9 CFU of *P. gingivalis* W50 or PG1424 or gavaged with vehicle alone on days 0 , 2 , and 4 . Twenty-four and 48 h after the first inoculation, mice were injected with arthritogenic K/BxN serum ($50 \mu\text{L}$, intraperitoneally) to initiate inflammatory arthritis. To assess the effects of inflammatory arthritis via gut barrier function, inoculation was performed straight into the stomach of the animals. While previous studies demonstrated that inflammatory arthritis leads to periodontal inflammation (Montero-Melendez et al. 2014), we did not observe differences in the macroscopic signs of periodontal inflammation among the groups (data not shown). 16S qPCR to measure bacterial DNA in gut-draining mesenteric lymph nodes, as a readout for microbial breach of the gut barrier (Flak et al. 2019), demonstrated that PG1424 inoculation increased levels of bacterial DNA in mesenteric lymph nodes, albeit to a marginally lesser extent than the wild-type strain (Fig. 3A). Next, we assessed clinical markers of joint inflammation in terms of redness and edema formation in ankles,

paws, and small joints. Here, inoculation with both *P. gingivalis* strains exacerbated edema formation, as determined by the swelling index representing cumulative paw and ankle width (Fig. 3B), and increased joint inflammation by day 8 after the initial inoculation when compared with vehicle-gavaged arthritic mice (Fig. 3C, D). Together, these results suggest that PPAD activity is not the virulence factor/mechanism underlying *P. gingivalis*-mediated gut barrier breakdown and disease exacerbation in inflammatory arthritis.

Discussion

In the present study, we demonstrate that autocitrullination of the *P. gingivalis* proteome is strictly dependent on the pathobiont's PPAD enzymatic activity. Contrary to the frequently proposed hypothesis, our findings suggest that this autocitrullination does not generate epitopes that represent antigenic targets for ACPA autoantibodies in the serum of DMARD-naïve early RA patients.

Increased immunoreactivity of RA patient sera against *P. gingivalis*-derived proteins has been reported (Mikulski et al. 2009; Bender et al. 2017) and correlations with ACPA levels observed, albeit not unanimously (Okada et al. 2011; Bae and Lee 2018). Yet, the mechanistic relevance of autocitrullinated *P. gingivalis* proteins in autoimmune responses in RA and their contribution to the onset of the disease remain unclear (Konig, Bingham, and Andrade 2015; Olsen et al. 2018).

Autocitrullinated PPAD has recently been investigated for its potential role in triggering loss of self-tolerance and induction of cross-reactive ACPA in RA (Quirke et al. 2014). Interestingly, studies by several groups have reported conflicting results with respect to the ability of PPAD to autocitrullinate and the antigenicity of such autocitrullinated PPAD in RA (Quirke et al. 2014; König, Bingham, and Andrade 2015). Using a colorimetric assay for citrullination, TLC, and immunoblotting, we found that autocitrullination of the *P. gingivalis* proteome occurs only in the presence of a functioning PPAD and was not detected on the proteome of a PPAD-deleted mutant *P. gingivalis* PG1424.

Our findings also indicate clear antibody reactivity against *P. gingivalis* W50 in serum from DMARD-naïve early RA patients and healthy individuals. Yet, despite the inability of mutant strain PG1424 to autocitrullinate its proteins, no differences were found in the pattern of reactivity of DMARD-naïve RA patient serum against lysates from wild-type *P. gingivalis* W50 or the PPAD-deleted mutant PG1424, regardless of patients' ACPA status. This suggests that while patient serum antibodies are likely to target proteins of the pathobiont that are autocitrullinated, the autocitrullinated residues themselves do

not serve as epitopes that are specifically targeted by ACPA. Although severity of arthritic disease is reportedly linked to the presence of periodontitis in susceptible individuals and, subsequently, RA symptoms may decrease following successful treatment of periodontal disease (Bingham and Moni 2013; Chou et al. 2015), our findings indicate that the effect of periodontitis on joint disease is not dependent on generation of epitopes within the autocitrullinated *P. gingivalis* proteome. However, while our data support the notion that this autocitrullinome does not act as a trigger of initial ACPA production as occurs during early stages of RA, we cannot rule out that autocitrullinated *P. gingivalis* proteins may contribute to autoimmune responses during later stages of disease (Kudo-Tanaka et al. 2007). Moreover, host-derived inflammatory cues, as may arise during periodontitis that is driven by *P. gingivalis* or other oral pathobionts but also nonmicrobial factors (Curtis et al. 2011), may induce posttranslational protein modifications, including citrullination and carbamylation (Bright et al. 2018), and thus could be a mechanism linking periodontitis and RA.

It is also possible that the absence of detectable RA patient antibody binding specifically to citrullinated epitopes within the autocitrullinome of *P. gingivalis* may be due to the levels of ACPA targeting these bacterial epitopes being extremely low and below the detection levels of our assays. This would imply that PPAD autocitrullination is not a trigger of strong (auto) immune responses, at least not during the early stages of RA. Moreover, epitopes generated by PPAD citrullination of *P. gingivalis* proteins may be structurally different to other types of citrullinated residues that are bound by ACPA or that the modified epitope may not be accessible to the antibody.

It is also possible that, rather than constituting an epitope for (auto)antibodies, citrullination and thus PPAD activity may instead contribute to the triggering of RA through other mechanisms, for example, by uncovering cryptic noncitrullinated epitopes by altering the secondary or tertiary structures of proteins (Koziel et al. 2014)—thus not through molecular mimicry but through what perhaps might be considered biofunctional mimicry. Alternatively, it has recently been reported that *P. gingivalis* PPAD may influence biofilm formation (Vermilyea et al. 2019) and gene expression in keratinocytes, although it is unclear whether citrullination is required for the latter (Aliko et al. 2018). Our recent discovery that impaired gut barrier function in the arthritic host facilitates pathogenic behavior of *P. gingivalis*, including intestinal barrier breakdown, promotion of gut microbial invasion, and exacerbation of joint inflammation, provides insights into the mechanisms underlying the connection between RA and periodontitis/*P. gingivalis*. Two previous studies with another model of inflammatory arthritis reported reduced exacerbation of joint inflammation after inoculation with PPAD-deleted *P. gingivalis* (Maresz et al. 2013; Gully et al. 2014). However, the first study, due to colonization resistance of the mouse strain used, required exposure of the immune system to *P. gingivalis* inside a subcutaneously implanted chamber, not via mucosal surfaces (Maresz et al. 2013). The second study involved antibiotic pretreatment prior to *P. gingivalis* inoculation, and induction of inflammatory arthritis took place after completion of a long

inoculation period over 4 wk (Gully et al. 2014). Results from the present study, where inoculation occurred in the gastrointestinal tract without antibiotic pretreatment and disease was initiated shortly after, suggest that the pathogenic actions of *P. gingivalis* on the gut barrier and joint inflammation are essentially independent of PPAD activity. This is in line with our previous studies demonstrating that *P. gingivalis* disrupts the gut barrier via downregulating epithelial barrier junctional proteins and those by Katz et al. (2002) demonstrating that in the oral mucosa this pathobiont can directly breakdown epithelial barrier proteins. Although there may be an initial delay, by day 8 after arthritis initiation, the PPAD mutant, like the wild-type strain, promotes microbial gut barrier breach and significantly exacerbates clinical symptoms of joint inflammation.

To conclude, our findings support the hypothesis (Konig, Paracha, et al. 2015) that the autocitrullinated *P. gingivalis* proteome does not contain strongly immunogenic epitopes targeted by serum ACPA during the early stages of RA and that PPAD activity is not required for the gut barrier breakdown underlying *P. gingivalis*-driven inflammatory arthritis.



Author Contributions

E. Muñoz-Atienza, M.B. Flak, contributed to conception, design, data acquisition, analysis, and interpretation, drafted the manuscript; J. Sirr, contributed to data acquisition and analysis, critically revised the manuscript; N.A. Paramonov, J. Aduse-Opoku, contributed to conception, design, data acquisition, analysis, and interpretation, critically revised the manuscript; C. Pitzalis, M.A. Curtis, contributed to conception and design, critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.

Acknowledgments

This work was supported by funding from Versus Arthritis (formerly Arthritis Research UK) to C.P. and M.A.C. (grant 21134) and to C.P. (grant 20022), from the Medical Research Council to M.A.C. (grants MR/P012175/1 and MR/P012175/2), and a Marie Skłodowska-Curie Individual Fellowship under the European Union's Horizon 2020 research and innovation program (grant 746183) to M.B.F. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.

ORCID iDs

E. Muñoz-Atienza  <https://orcid.org/0000-0001-6218-1511>
M.B. Flak  <https://orcid.org/0000-0002-8238-9835>

References

- Aduse-Opoku J, Slaney JM, Hashim A, Gallagher A, Gallagher RP, Rangarajan M, Boutaga K, Laine ML, Van Winkelhoff AJ, Curtis MA. 2006. Identification and characterization of the capsular polysaccharide (K-antigen) locus of *Porphyromonas gingivalis*. *Infect Immun*. 74(1):449–460.
- Aliko A, Kaminska M, Bergum B, Gawron K, Benedyk M, Lamont RJ, Malicki S, Delaleu N, Potempa J, Mydel P. 2018. Impact of *Porphyromonas gingivalis* peptidylarginine deiminase on bacterial biofilm formation, epithelial cell invasion, and epithelial cell transcriptional landscape. *Sci Rep*. 8(1):14144.

- Bae SC, Lee YH. 2018. Association between anti-*Porphyromonas gingivalis* antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: a meta-analysis. *Z Rheumatol*. 77(6):522–532.
- Bender P, Burgin WB, Sculean A, Eick S. 2017. Serum antibody levels against *Porphyromonas gingivalis* in patients with and without rheumatoid arthritis—a systematic review and meta-analysis. *Clin Oral Investig*. 21(1):33–42.
- Bingham CO 3rd, Moni M. 2013. Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions. *Curr Opin Rheumatol*. 25(3):345–353.
- Bright R, Thiele GM, Manavis J, Mikuls TR, Payne JB, Bartold PM. 2018. Gingival tissue, an extrasynovial source of malondialdehyde-acetaldehyde adducts, citrullinated and carbamylated proteins. *J Periodontol Res*. 53(1):139–143.
- Cai X, Jiang H, Zhang T, Jiang B, Mu W, Miao M. 2018. Thermostability and specific-activity enhancement of an arginine deiminase from *Enterococcus faecalis* SK23.001 via semirational design for L-citrulline production. *J Agric Food Chem*. 66(33):8841–8850.
- Casiano-Colon A, Marquis RE. 1988. Role of the arginine deiminase system in protecting oral bacteria and an enzymatic basis for acid tolerance. *Appl Environ Microbiol*. 54(6):1318–1324.
- Chou YY, Lai KL, Chen DY, Lin CH, Chen HH. 2015. Rheumatoid arthritis risk associated with periodontitis exposure: a nationwide, population-based cohort study. *PLoS One*. 10(10):e0139693.
- Condorelli F, Scalia G, Cali G, Rossetti B, Nicoletti G, Lo Bue AM. 1998. Isolation of *Porphyromonas gingivalis* and detection of immunoglobulin a specific to fimbrial antigen in gingival crevicular fluid. *J Clin Microbiol*. 36(8):2322–2325.
- Curtis MA, Aduse Opoku J, Rangarajan M, Gallagher A, Sterne JA, Reid CR, Evans HE, Samuelsson B. 2002. Attenuation of the virulence of *Porphyromonas gingivalis* by using a specific synthetic Kgp protease inhibitor. *Infect Immun*. 70(12):6968–6975.
- Curtis MA, Zenobia C, Darveau RP. 2011. The relationship of the oral microbiota to periodontal health and disease. *Cell Host Microbe*. 10(4):302–306.
- Diez L, Solopova A, Fernández-Pérez R, González M, Tenorio C, Kuipers OP, Ruiz-Larrea F. 2017. Transcriptome analysis shows activation of the arginine deiminase pathway in *Lactococcus lactis* as a response to ethanol stress. *Int J Food Microbiol*. 257:41–48.
- Flak MB, Colas RA, Muñoz-Atienza E, Curtis MA, Dalli J, Pitzalis C. 2019. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by *Porphyromonas gingivalis*. *JCI insight*. 4(13):125191.
- Goulas T, Mizgalska D, Garcia-Ferrer I, Kantyka T, Guevara T, Szmigielski B, Sroka A, Millán C, Usón I, Veillard F, et al. 2015. Structure and mechanism of a bacterial host-protein citrullinating virulence factor, *Porphyromonas gingivalis* peptidylarginine deiminase. *Sci Rep*. 5:11969.
- Gully N, Bright R, Marino V, Marchant C, Cantley M, Haynes D, Butler C, Dashper S, Reynolds E, Bartold M. 2014. *Porphyromonas gingivalis* peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis. *PLoS One*. 9(6):e100838.
- Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskin MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD, et al. 2011. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. *Cell Host Microbe*. 10(5):497–506.
- Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P. 2006. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology*. 45(1):106–111.
- Katz J, Yang QB, Zhang P, Potempa J, Travis J, Michalek SM, Balkovetz DF. 2002. Hydrolysis of epithelial junctional proteins by *Porphyromonas gingivalis* gingipains. *Infect Immun*. 70(5):2512–2518.
- Konig MF, Bingham CO 3rd, Andrade F. 2015. PPAD is not targeted as a citrullinated protein in rheumatoid arthritis, but remains a candidate for inducing autoimmunity. *Ann Rheum Dis*. 74(1):e8.
- Konig MF, Paracha AS, Moni M, Bingham CO 3rd, Andrade F. 2015. Defining the role of *Porphyromonas gingivalis* peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. *Ann Rheum Dis*. 74(11):2054–2061.
- Koziel J, Mydel P, Potempa J. 2014. The link between periodontal disease and rheumatoid arthritis: an updated review. *Curr Rheumatol Rep*. 16(3):408.
- Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, et al. 2007. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. *Clin Rheumatol*. 26(10):1627–1633.
- Maeda Y, Takeda K. 2017. Role of gut microbiota in rheumatoid arthritis. *J Clin Med*. 6(6):E60.
- Maresz KJ, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, Gawron K, Mizgalska D, Marcinska KA, Benedyk M, et al. 2013. *Porphyromonas gingivalis* facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). *PLoS Pathog*. 9(9):e1003627.
- Masson-Bessiere C, Sebbag M, Girbal-Neuhausser E, Nogueira L, Vincent C, Senshu T, Serre G. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deaminated forms of the alpha- and beta-chains of fibrin. *J Immunol*. 166(6):4177–4184.
- McGraw WT, Potempa J, Farley D, Travis J. 1999. Purification, characterization, and sequence analysis of a potential virulence factor from *Porphyromonas gingivalis*, peptidylarginine deiminase. *Infect Immun*. 67(7):3248–3256.
- Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, Holers VM, Kuhn KA, O'Dell JR. 2009. Antibody responses to *Porphyromonas gingivalis* (*P. gingivalis*) in subjects with rheumatoid arthritis and periodontitis. *Int Immunopharmacol*. 9(1):38–42.
- Montero-Melendez T, Madeira MFM, Norling LV, Alsam A, Curtis MA, da Silva TA, Perretti M. 2014. Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3. *Am J Pathol*. 184(8):2333–2341.
- Montgomery AB, Kopec J, Shrestha L, Thezenas ML, Burgess-Brown NA, Fischer R, Yue WW, Venables PJ. 2016. Crystal structure of *Porphyromonas gingivalis* peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis. *Ann Rheum Dis*. 75(6):1255–1261.
- Okada M, Kobayashi T, Ito S, Yokoyama T, Komatsu Y, Abe A, Murasawa A, Yoshie H. 2011. Antibody responses to periodontopathic bacteria in relation to rheumatoid arthritis in Japanese adults. *J Periodontol*. 82(10):1433–1441.
- Olsen I, Singhrao SK, Potempa J. 2018. Citrullination as a plausible link to periodontitis, rheumatoid arthritis, atherosclerosis and Alzheimer's disease. *J Oral Microbiol*. 10(1):1487742.
- Quirke AM, Lugli EB, Wegner N, Hamilton BC, Charles P, Chowdhury M, Ytterberg AJ, Zubarev RA, Potempa J, Culshaw S, et al. 2014. Heightened immune response to autocitrullinated *Porphyromonas gingivalis* peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. *Ann Rheum Dis*. 73(1):263–269.
- Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum*. 48(10):2741–2749.
- Romero V, Fert-Bober J, Nigrovic PA, Darrach E, Haque UJ, Lee DM, van Eyk J, Rosen A, Andrade F. 2013. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. *Sci Transl Med*. 5(209):209ra150.
- Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. 2004. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. *Inflammation*. 28(6):311–318.
- Sakkas LI, Daoussis D, Liossis SN, Bogdanos DP. 2017. The infectious basis of ACPA-positive rheumatoid arthritis. *Front Microbiol*. 8:1853.
- Shi J, Willemze A, Janssen GM, van Veelen PA, Drijfhout JW, Cerami A, Huizinga TW, Trouw LA, Toes RE. 2013. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the “AMC-Senshu” method. *Ann Rheum Dis*. 72(1):148–150.
- Vermilyea DM, Ottenberg GK, Davey ME. 2019. Citrullination mediated by PPAD constrains biofilm formation in *P. gingivalis* strain 381. *NPJ Biofilms Microbiomes*. 5:7.
- Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, Kinloch A, Culshaw S, Potempa J, Venables PJ. 2010. Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and α -enolase: implications for autoimmunity in rheumatoid arthritis. *Arthritis Rheum*. 62(9):2662–2672.